
Topic
Oncology
HER2-targeted therapy, tumor-type access, buy-and-bill reimbursement, oncology biosimilars, and cancer drug coverage.

Pricing & Access· May 27, 2026 · 11 min read

Biosimilars· May 27, 2026 · 12 min read
Neulasta biosimilars coding and reimbursement guide
By Ran Chen#Biosimilars#HCPCS Coding#Oncology

Pricing & Access· May 27, 2026 · 10 min read
Opdivo Qvantig vs IV Opdivo access guide
By Ran Chen#Oncology#Prior Authorization#Payer Policy

Pricing & Access· May 27, 2026 · 9 min read
Padcev plus Keytruda urothelial cancer access guide

Pricing & Access· May 27, 2026 · 12 min read
Prolia and Xgeva denosumab biosimilars guide
By Ran Chen#Biosimilars#Payer Policy#HCPCS Coding

Pricing & Access· May 27, 2026 · 9 min read
Trodelvy access guide for breast cancer coverage
By Ran Chen#Oncology#ADC#Prior Authorization

Pricing & Access· May 27, 2026 · 12 min read
Yescarta vs Tecartus CAR-T access guide
By Ran Chen#Oncology#CAR-T#Prior Authorization

Pricing & Access· May 26, 2026 · 7 min read
Veppanu coverage guide for ER+/HER2- breast cancer
By Ran Chen#PROTAC#Breast Cancer#Companion Diagnostic

Biosimilars· May 22, 2026 · 9 min read
Avastin biosimilars: FDA status, interchangeability, payer coverage, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Pipeline· May 22, 2026 · 13 min read
Compendia listing gaps for oncology access before label expansion
By Ran Chen#Oncology#Market Access#Medicare Part D